Urticaria in COVID-19 Patient Treated with Lopinavir / Ritonavir : A Case Report

Authors

  • Prof. Cita Rosita Sigit Prakoeswa, MD, PhD Department of Dermatology and Venereology, Airlangga University / Dr. Soetomo General Academic Hospital, Surabaya – Indonesia
  • Damayanti, MD, PhD Department of Dermatology and Venereology, Airlangga University / Dr. Soetomo General Academic Hospital, Surabaya – Indonesia
  • Sylvia Anggraeni, MD Department of Dermatology and Venereology, Airlangga University / Dr. Soetomo General Academic Hospital, Surabaya – Indonesia
  • Menul Ayu Umborowati, MD Department of Dermatology and Venereology, Airlangga University / Dr. Soetomo General Academic Hospital, Surabaya – Indonesia
  • Medhi Denisa Alinda, MD Department of Dermatology and Venereology, Airlangga University / Dr. Soetomo General Academic Hospital, Surabaya – Indonesia
  • Natalia Tanojo, MD Department of Dermatology and Venereology, Airlangga University / Dr. Soetomo General Academic Hospital, Surabaya – Indonesia
  • Jonggi Mathias Rajapikir Tamba, MD Department of Dermatology and Venereology, Airlangga University / Dr. Soetomo General Academic Hospital, Surabaya – Indonesia
  • Bernadya Yogatri, MD Department of Dermatology and Venereology, Airlangga University / Dr. Soetomo General Academic Hospital, Surabaya – Indonesia
  • Soedarsono, MD, PhD Department of Pulmonology, Airlangga University / Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
  • Ariani Permatasari, MD Department of Pulmonology, Airlangga University / Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
  • Bambang Pujo Semedi, MD Departement of Anesthesiology and Reanimation, Airlangga University / Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

DOI:

https://doi.org/10.66344/jpad.31.4.2021.1773

Abstract

  The unknown pneumonia was first found in Wuhan, China in December 2019. A novel corona virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated from lower respiratory tract swab in infected patient. The disease caused by this novel virus was then named as COVID-19 (Coronavirus Disease 2019). We report a male patient with urticarial lesions, varies on size and shape on the both arms and both legs and diagnosed with COVID-19 confirmed case. He was treated with powdered oral medicine containing combination of lopinavir and ritonavir.  He developed urticarial lesions in three hours after administration of the drug. The lesions then dissapeared and resolved after 4 days of treatment using cetirizine. The conclusion of this case is still needed to be proven whether the urticarial lesion is related to COVID-19 or drugs used for COVID-19 therapy.   Keywords: COVID-19, urticarial drug eruption, lopinavir, ritonavir, infectious disease.

Downloads

Published

2022-03-29

How to Cite

1.
Prof. Cita Rosita Sigit Prakoeswa, MD, PhD, Damayanti, MD, PhD, Sylvia Anggraeni, MD, Menul Ayu Umborowati, MD, Medhi Denisa Alinda, MD, Natalia Tanojo, MD, Jonggi Mathias Rajapikir Tamba, MD, Bernadya Yogatri, MD, Soedarsono, MD, PhD, Ariani Permatasari, MD, Bambang Pujo Semedi, MD. Urticaria in COVID-19 Patient Treated with Lopinavir / Ritonavir : A Case Report. J Pak Assoc Dermatol [Internet]. 2022Mar.29 [cited 2026Apr.8];31(4):725-30. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1773

Issue

Vol. 31 No. 4 (2021): October - December

Section

Case Reports

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.

Most read articles by the same author(s)